Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | M032 |
Synonyms | |
Therapy Description |
M032 is an oncolytic herpes simplex virus-1 (HSV-1) engineered to express IL-12, which may result in increased anti-tumor immune response and decreased tumor cells proliferation (PMID: 33524948; NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
M032 | M 032|M-032|NSC 733972 | M032 is an oncolytic herpes simplex virus-1 (HSV-1) engineered to express IL-12, which may result in increased anti-tumor immune response and decreased tumor cells proliferation (PMID: 33524948; NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02062827 | Phase I | M032 | Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma (M032-HSV-1) | Active, not recruiting | USA | 0 |